Estuardo Aguilar-Cordova - 26 Jul 2021 Form 3 Insider Report for Candel Therapeutics, Inc. (CADL)

Role
Chief Scientific Officer, Director
Signature
/s/ Estuardo Aguilar-Cordova
Issuer symbol
CADL
Transactions as of
26 Jul 2021
Net transactions value
$0
Form type
3
Filing time
26 Jul 2021, 21:21:42 UTC
Next filing
02 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CADL Common Stock 853,786 26 Jul 2021 Direct
holding CADL Common Stock 2,074,942 26 Jul 2021 By Estuardo Aguilar-Cordova 2020 Irrevocable Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CADL Stock Option (Right to Buy) 26 Jul 2021 Common Stock 12,205 $1.46 Direct F2
holding CADL Stock Option (Right to Buy) 26 Jul 2021 Common Stock 76,717 $1.46 Direct F3
holding CADL Series B Preferred Stock 26 Jul 2021 Common Stock 162,137 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares held by the Estuardo Aguilar-Cordova 2020 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
F2 25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in three substantially equal annual installments thereafter.
F3 This option shall vest and become exercisable in four substantially equal annual installments, with the first installment vesting on October 13, 2018.
F4 The Series B Preferred Stock has no expiration date.
F5 Includes 32,399 shares held jointly with spouse.